Damora Therapeutics, Inc.
Support and Resistance Levels
Past performance
News About DMRA
All events for DMRA
All deals for DMRA
Financial Ratios
Financial Statements
DMRA vs Sector & Peers
About Damora Therapeutics, Inc.
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts. Website damoratx.com
Headquarters Waltham, MA, US